Haze K - Search Results

1

Endoplasmic reticulum stress-induced formation of transcription factor complex ERSF including NF-Y (CBF) and activating transcription factors 6alpha and 6beta that activates the mammalian unfolded protein response.

Yoshida H, Okada T, Haze K, Yanagi H, Yura T, Negishi M, Mori K. Yoshida H, et al. Among authors: haze k. Mol Cell Biol. 2001 Feb;21(4):1239-48. doi: 10.1128/MCB.21.4.1239-1248.2001. Mol Cell Biol. 2001. PMID: 11158310 Free PMC article.

2

A serine protease inhibitor prevents endoplasmic reticulum stress-induced cleavage but not transport of the membrane-bound transcription factor ATF6.

Okada T, Haze K, Nadanaka S, Yoshida H, Seidah NG, Hirano Y, Sato R, Negishi M, Mori K. Okada T, et al. Among authors: haze k. J Biol Chem. 2003 Aug 15;278(33):31024-32. doi: 10.1074/jbc.M300923200. Epub 2003 Jun 2. J Biol Chem. 2003. PMID: 12782636 Free article.

3

Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors.

Yoshida H, Haze K, Yanagi H, Yura T, Mori K. Yoshida H, et al. Among authors: haze k. J Biol Chem. 1998 Dec 11;273(50):33741-9. doi: 10.1074/jbc.273.50.33741. J Biol Chem. 1998. PMID: 9837962 Free article.

4

Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress.

Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Haze K, et al. Mol Biol Cell. 1999 Nov;10(11):3787-99. doi: 10.1091/mbc.10.11.3787. Mol Biol Cell. 1999. PMID: 10564271 Free PMC article.

5

ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response.

Yoshida H, Okada T, Haze K, Yanagi H, Yura T, Negishi M, Mori K. Yoshida H, et al. Among authors: haze k. Mol Cell Biol. 2000 Sep;20(18):6755-67. doi: 10.1128/MCB.20.18.6755-6767.2000. Mol Cell Biol. 2000. PMID: 10958673 Free PMC article.

6

Identification of the G13 (cAMP-response-element-binding protein-related protein) gene product related to activating transcription factor 6 as a transcriptional activator of the mammalian unfolded protein response.

Haze K, Okada T, Yoshida H, Yanagi H, Yura T, Negishi M, Mori K. Haze K, et al. Biochem J. 2001 Apr 1;355(Pt 1):19-28. doi: 10.1042/0264-6021:3550019. Biochem J. 2001. PMID: 11256944 Free PMC article.

7

Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.

Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y. Sato Y, et al. Among authors: haze k. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4673-8. doi: 10.1016/j.bmcl.2009.06.084. Epub 2009 Jun 25. Bioorg Med Chem Lett. 2009. PMID: 19589677

8

Identification of beta-catenin as a novel substrate of Polo-like kinase 1.

Arai T, Haze K, Iimura-Morita Y, Machida T, Iida M, Tanaka K, Komatani H. Arai T, et al. Among authors: haze k. Cell Cycle. 2008 Nov 15;7(22):3556-63. doi: 10.4161/cc.7.22.7072. Epub 2008 Nov 26. Cell Cycle. 2008. PMID: 19001871

9

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.

Hirai H, Shimomura T, Kobayashi M, Eguchi T, Taniguchi E, Fukasawa K, Machida T, Oki H, Arai T, Ichikawa K, Hasako S, Haze K, Kodera T, Kawanishi N, Takahashi-Suziki I, Nakatsuru Y, Kotani H, Iwasawa Y. Hirai H, et al. Among authors: haze k. Cell Cycle. 2010 Apr 15;9(8):1590-600. doi: 10.4161/cc.9.8.11306. Epub 2010 Apr 15. Cell Cycle. 2010. PMID: 20372067

10

Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey).

Teramoto T, Ogawa H, Ueshima H, Okada Y, Haze K, Matsui S, Fujikawa K, Hashimoto T, Sakui S, Nishimura K, Kajita M, Horimoto A, Fernandez J. Teramoto T, et al. Among authors: haze k. Expert Opin Drug Saf. 2023 Jan;22(1):81-90. doi: 10.1080/14740338.2022.2094914. Epub 2022 Jul 8. Expert Opin Drug Saf. 2023. PMID: 35772177 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

232 results

Search Page